Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Tessier

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsSuzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Oncotarget|June 7, 2018
<sup>89</sup>Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-bindingEmilie M J van Brummelen, Marc C Huisman, Linda J de Wit-van der Veen, et al.
Cancer Research|May 16, 2020
The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody TreatmentChristoph M Griessinger, Tove Olafsen, Alessandro Mascioni, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsSuzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Oncotarget|June 7, 2018
<sup>89</sup>Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-bindingEmilie M J van Brummelen, Marc C Huisman, Linda J de Wit-van der Veen, et al.
Cancer Research|May 16, 2020
The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody TreatmentChristoph M Griessinger, Tove Olafsen, Alessandro Mascioni, et al.
Pageof 2